Supplementary Figure 10: Kaplan-Meier analysis of the survival of people with NKTCL, excluding extranasal cases or stage III and stage IV cases.
From: Exome sequencing identifies somatic mutations of DDX3X in natural killer/T-cell lymphoma
(a) Overall survival (OS) and progression-free survival (PFS) of NKTCL patients excluding extranasal cases according to mutation status of DDX3X and TP53 (upper panel) and according to risk stratification combining International Prognostic Index (IPI) and mutation status of DDX3X and TP53 (lower panel). (b) OS and PFS of NKTCL patients excluding stage III–IV cases according to mutation status of DDX3X and TP53 (upper panel) and according to risk stratification combining IPI and mutation status of DDX3X and TP53 (lower panel). Risk stratification combining IPI and mutation status of DDX3X and TP53: Group 1: IPI0–1 and wtDDX3X/wtTP53; Group 2: IPI0–1 and mutDDX3X/mutTP53 or IPI2–5 and wtDDX3X/wtTP53; Group 3: IPI2–5 and mutDDX3X/mutTP53. wt: wild-type, individuals without DDX3X or TP53 mutations; mut: mutation, individuals with DDX3X or TP53 mutations. One individual with both DDX3X and TP53 mutations was grouped into two cohorts with mutations.
